Hovanessian A G, Rivière Y, Montagnier L, Michelson M, Lacour J, Lacour F
J Interferon Res. 1982;2(2):209-15. doi: 10.1089/jir.1982.2.209.
Interferon-treated mouse and human cells show enhanced levels of kinase activity manifested by the phosphorylation of endogenous 67,000 (p67K kinase) and 72,000 (p72K kinase) molecular weight proteins, respectively. Both the p67K kinase and the p72K activities are detectable in mouse and human plasma. We have previously shown that the p67K kinase in the plasma of mice may serve as a marker for the presence and action of interferon. Here we show that these kinase activities are enhanced in mice and in patients treated with polyadenylic-polyuridylic acid (Poly A:Poly U) at doses (0.4-0.6 mg/kg body weight) which do not lead to detectable amount of circulating interferon. Mice injected with higher doses of Poly A:Poly U (2-10 mg/kg body weight) show detectable levels of circulating interferon in addition to enhanced levels of p67K kinase in their plasma. Interferon produced under these conditions is acid stable.
经干扰素处理的小鼠和人类细胞显示出激酶活性水平增强，分别表现为内源性分子量为67,000（p67K激酶）和72,000（p72K激酶）的蛋白质发生磷酸化。p67K激酶和p72K活性在小鼠和人类血浆中均可检测到。我们之前已经表明，小鼠血浆中的p67K激酶可能作为干扰素存在和作用的标志物。在此我们表明，在用聚腺苷酸-聚尿苷酸（Poly A:Poly U）（0.4-0.6毫克/千克体重）治疗的小鼠和患者中，这些激酶活性增强，而该剂量不会导致可检测到的循环干扰素量。注射更高剂量Poly A:Poly U（2-10毫克/千克体重）的小鼠，其血浆中除了p67K激酶水平增强外，还显示出可检测到的循环干扰素水平。在这些条件下产生的干扰素对酸稳定。
